RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Shanghai’s I-Mab BioPharma has submitted an IND in China for approval to conduct clinical trials of its immuno-oncology multiple myeloma treatment. TJ202/MOR202 is a mAb that is directed against CD38, activating the immune system’s killer cells. One year ago, I-Mab in-licensed China rights to the candidate from Germany’s MorphoSys in a $120 million agreement. MorphoSys has started Phase II trials of the drug in Germany and Austria.
Source: China Biotoday
